Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617949 | 1.00 | HPGD (0.44) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16617541 | 0.88 | ABL1 (0.45) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16617175 | 0.82 | PTGER4 (0.38) | SMN1; SMN2ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL16617178 | 0.82 | PTGER4 (0.38) | SMN1; SMN2ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL16617856 | 0.81 | ALDH1A1 (0.41) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16617855 | 0.81 | ALDH1A1 (0.41) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL16617132 | 0.80 | KMT2A (0.41) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL16617133 | 0.80 | KMT2A (0.41) | HPGDSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16618087 | 0.79 | KDM1A (0.37) | ALDH1A1KMT2A | |
| SCHEMBL16618089 | 0.79 | KDM1A (0.37) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | HPGD 3020/4885SMN1; SMN2 4512/4885ALDH1A1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.